Merck Animal Health Receives 2016 Nebraska Governor’s Bioscience Award

MADISON, N.J., April 29, 2016 – Merck Animal Health is pleased to announce that the Bio Nebraska Life Sciences Association (BNLSA) has selected the company as the recipient of the 2016 Governor’s Bioscience Award. The award, which recognizes significant contributions to Nebraska’s bioscience industry and overall economy, is given to an organization that has made a considerable impact on the state through innovation, business creation, investment and leadership. It is the highest honor bestowed by Bio Nebraska and was presented by Governor Pete Ricketts.
“This distinctive award is a testament to the pioneering work our employees are doing every day within our company’s Nebraska-based facilities, as well as our long-standing commitment to investing in the communities in which we work and live,” said Scott Bormann, Vice President, North America, Merck Animal Health. “We are extremely honored by this recognition and are proud to partner with BNLSA in the ongoing advancement of science and technology, and the creation of economic development opportunities.”
Merck Animal Health’s Nebraska-based facilities are both deemed “Centers of Excellence” for companion animal and poultry research and development. The team was instrumental in the rapid development and licensing of the company’s Canine Influenza H3N2 vaccine to promptly address an outbreak of the H3N2 strain of the disease, which had never been seen in the United States. In addition, the team’s innovative work in poultry vaccines is helping producers provide optimal care to their flocks, while also supporting our ongoing commitment to the science of healthier animals.
Bio Nebraska champions technology while advocating for its member organizations by promoting academic, industry and government partnerships to foster the growth of life sciences within the state.

About Merck Animal Health

For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (